

## **RenalGuard Solutions Signs Distribution Agreement with Kaneka Pharma Europe NV**

- Kaneka Pharma Europe NV (KPE) to market and distribute RenalGuard in Europe, the Middle East and Africa
- Improves access to breakthrough treatment option through both direct channels as well as a wide network of agents

MILFORD, MA – March 27, 2020 – RenalGuard Solutions™, a pioneering medical device company focused on protecting patients from acute kidney injury (AKI), today announced that Kaneka Corporation, through its wholly-owned subsidiary Kaneka Pharma Europe NV, has agreed to be the exclusive multinational distributor of the company’s technology in Europe, the Middle East and Africa.

Under the terms of the agreement, KPE will employ its sales, marketing and e-commerce expertise to distribute the RenalGuard System and associated supplies. KPE is uniquely positioned to build out further target market distribution, as well as, seamlessly partner with several of RenalGuard’s highly successful distributors.

“We are very excited to join forces with KPE, a leading medical solutions provider, to expand our customer base for RenalGuard,” said Jim Dillon, President and Chief Executive Officer, RenalGuard Solutions. “The system has been used in over 30,000 coronary and peripheral interventions to date, and partnering with the Kaneka team, will enable us to substantially increase the number of patients treated to reduce the incidence of Post Contrast Acute Kidney Injury (PC-AKI).”

“Kaneka is impressed with RenalGuard’s proprietary expertise in protecting patients against renal injury. Combining this unique therapy with our growing cardiac, peripheral and neuro portfolio will enable many more at-risk patients to benefit from Kaneka’s lifesaving technologies,” stated Takuji Hasegawa, Vice President, Kaneka Pharma Europe NV.

A recent study, *Hydration Strategies for Preventing Contrast-Induced Acute Kidney Injury: A Systematic Review and Bayesian Network Meta-Analysis*, concluded that there is substantial evidence to support the use of RenalGuard or hemodynamic guided hydration to prevent CI-AKI in high-risk patients, especially those with chronic kidney disease (CKD) or cardiac dysfunction.

Kaneka Corporation provides solutions for people, society, and the global environment in four business areas:

- Quality of Life
- Health Care
- Nutrition
- Materials

The Company operates sales/manufacturing across the globe including Japan, the EMEA region, Vietnam, Malaysia, Singapore, and US.

RenalGuard will be marketed and sold as part of Kaneka's Health Care Solutions Unit and interventional cardiology business. KPE plans to leverage RenalGuard's current market penetration to expand to additional countries for both RenalGuard and KPE's catheter solutions business.

**About RenalGuard Solutions, Inc.**

Milford, MA-based RenalGuard Solutions, Inc. is a medical device company focused on innovative technologies for the cardiac and vascular markets. The company's RenalGuard Therapy is designed to prevent surgical or procedure-induced acute kidney injury (AKI), as well as contrast-induced nephropathy (CIN) for at-risk patients undergoing interventional procedures using contrast. For more information, please visit [www.renanguard.com](http://www.renanguard.com).

Media Contact:

Gregory W. Mann  
RenalGuard Solutions, Inc.  
(508) 520-2544  
[gmann@renanguard.com](mailto:gmann@renanguard.com)